United Therapeutics (UTHR) announced that ten posters and presentations across its commercial and development portfolio will be presented at ...

CHICAGO -- Adding sotatercept (Winrevair) to the treatment regimen for pulmonary arterial hypertension (PAH) in high-risk ...

RESEARCH TRIANGLE PARK, N.C., April 04, 2025--United Therapeutics Corporation (Nasdaq ... at the International Society for Heart and Lung Transplantation (ISHLT) 45th Annual Meeting and Scientific ...

In accordance with the NMPA approval, Gyre intends to pursue an adaptive Phase 2/3 clinical trial design, combining dose exploration with efficacy confirmation, to efficiently evaluate pirfenidone's ...

We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a ...

Carisma Therapeutics (NASDAQ:CARM – Get Free Report) had its price objective cut by equities researchers at D. Boral Capital from $12.00 to $1.00 in a report issued on Tuesday,Benzinga reports. The ...

The interim results of a phase 3 trial of Merck’s pulmonary arterial hypertension (PAH) treatment Winrevair were so ...

It was a busy week in the biotech sector, marked by significant regulatory and pipeline updates. Among these, shares of ...

Learn more about whether Blueprint Medicines Corporation or Moderna, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.